arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Spyre Therapeutics, Inc.

SYRE Health Care Biotechnology: Pharmaceutical Preparations
$90.68
▲ +1.9% Today
as of Sep 4, 16:55 ET
Last 30 days -10.98% Jul 28 → Sep 04
$85.30 $91.64 $97.99 $104.33 $110.67 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$86.45
High
$89.18
Low
$84.68
Volume
$776,149
Avg Vol
$1M
Mkt Cap
$9.0B
P/E (TTM)
—
Beta
—
52w High
$110.17
52w Low
$14.51
Div Yield
—
Shares Out
$88M

Recent Press Releases & News last 60 days · 25 items

Sep 4 · 20:01 PR GlobeNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
Sep 4 · 07:41 MT Newswires
Spyre Therapeutics Insider Sold Shares Worth $2,480,529, According to a Recent SEC Filing
Sep 4 · 07:30 MT Newswires
Spyre Therapeutics Insider Sold Shares Worth $2,283,821, According to a Recent SEC Filing
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$15
$110
80% of range
Avg surprise (last 3)
+7.8%
Avg reaction (last 2)
+2.0%
100% positive
Latest IV / EM
74%
EM ±11.5% · $90 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-4.89$6.37$17.62$28.88$40.14 Actual $-4.89Actual $40.14Actual $0.86Actual $0.72Actual $0.59Actual $1.06Actual $-0.74Est $-0.76Actual $-0.49Est $-0.73Actual $-0.74Est $-0.66 MarJunSepMarJunSepMar/2025Jun/2025Mar/2026
Revenue vs Net Income Revenue Net income
$-69M$-55M$-40M$-26M$-12M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue May 5, 2026Mar/2026 $-0.74 $-0.66 -12.1% 0.0% +2.7% earnings
Tue Aug 5, 2025Jun/2025 $-0.49 $-0.73 +32.9% — — earnings
Thu May 8, 2025Mar/2025 $-0.74 $-0.76 +2.6% — +1.2% earnings
Mon Sep 30, 2024Sep 2024 $1.06 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.59 — — — — financials
Sun Mar 31, 2024Mar 2024 $0.72 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.86 — — — — financials
Fri Jun 30, 2023Jun 2023 $40.14 — — — — financials
Fri Mar 31, 2023Mar 2023 $-4.89 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———————$0
Cost of revenue————————
Gross profit————————
Operating income$-42M$-46M—$-57M$-42M$-54M—$-55M
Net income$-36M$-69M—$-11M$-37M$-45M—$-69M
EPS (diluted)—$-0.74—————$1.06

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$162M$97M$86M$65M$82M$48M$89M$72M
Inventory————————
Total current assets$1.17B$764M$778M$505M$539M$570M$608M$421M
Total assets$1.17B$764M$778M$505M$539M$570M$608M$421M
Long-term debt————————
Total liabilities$72M$93M$63M$50M$83M$87M$91M$94M
Total equity$1.10B$671M$715M$455M$456M$483M$518M$327M

Implied volatility — last 90 days

64%88%112%137%161% Jun 07 — IV 90% · EM ±12.5%Jun 08 — IV 80% · EM ±10.5%Jun 09 — IV 71% · EM ±8.9%Jun 10 — IV 79% · EM ±9.3%Jun 11 — IV 81% · EM ±8.9%Jun 12 — IV 90% · EM ±9.2%Jun 15 — IV 83% · EM ±6.0%Jun 16 — IV 115% · EM ±6.8%Jun 17 — IV 161% · EM ±6.7%Jun 19 — IV 79% · EM ±17.4%Jun 22 — IV 80% · EM ±16.7%Jun 23 — IV 77% · EM ±15.8%Jun 24 — IV 77% · EM ±15.5%Jun 25 — IV 79% · EM ±15.4%Jun 26 — IV 77% · EM ±14.7%Jun 29 — IV 74% · EM ±13.2%Jun 30 — IV 73% · EM ±12.5%Jul 01 — IV 73% · EM ±12.3%Jul 02 — IV 69% · EM ±11.1%Jul 03 — IV 71% · EM ±11.1%Jul 06 — IV 76% · EM ±10.5%Jul 07 — IV 78% · EM ±10.2%Jul 08 — IV 79% · EM ±9.9%Jul 09 — IV 75% · EM ±8.8%Jul 10 — IV 75% · EM ±8.3%Jul 13 — IV 85% · EM ±7.1%Jul 14 — IV 71% · EM ±5.2%Jul 15 — IV 93% · EM ±5.5%Jul 16 — IV 132% · EM ±5.5%Jul 20 — IV 81% · EM ±19.2%Jul 21 — IV 77% · EM ±17.8%Jul 22 — IV 77% · EM ±17.5%Jul 23 — IV 80% · EM ±18.0%Jul 24 — IV 81% · EM ±17.9%Jul 27 — IV 82% · EM ±17.0%Jul 28 — IV 84% · EM ±17.1%Jul 29 — IV 83% · EM ±16.7%Jul 30 — IV 83% · EM ±16.2%Jul 31 — IV 83% · EM ±15.8%Aug 03 — IV 87% · EM ±15.4%Aug 04 — IV 94% · EM ±16.2%Aug 05 — IV 70% · EM ±11.7%Aug 06 — IV 72% · EM ±11.6%Aug 07 — IV 70% · EM ±10.9%Aug 10 — IV 69% · EM ±9.6%Aug 11 — IV 72% · EM ±9.5%Aug 12 — IV 73% · EM ±9.2%Aug 13 — IV 149% · EM ±17.6%Aug 14 — IV 69% · EM ±7.6%Aug 17 — IV 87% · EM ±7.3%Aug 18 — IV 87% · EM ±6.3%Aug 19 — IV 86% · EM ±5.1%Aug 20 — IV 134% · EM ±5.6%Aug 24 — IV 109% · EM ±22.8%Aug 25 — IV 137% · EM ±28.1%Aug 26 — IV 76% · EM ±15.2%Aug 27 — IV 78% · EM ±15.3%Aug 28 — IV 69% · EM ±13.1%Aug 31 — IV 70% · EM ±12.4%Sep 01 — IV 74% · EM ±12.8%Sep 02 — IV 71% · EM ±11.8%Sep 03 — IV 64% · EM ±10.4%Sep 04 — IV 74% · EM ±11.5%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in